M
Mahana Therapeutics
Developing digital treatments for people living with chronic health conditions
About Mahana Therapeutics
Mahanatx is a digital health startup that operates in the healthcare technology market. The company specializes in creating self-guided digital programs designed to help patients manage their health conditions. Their first product, Mahana™ IBS, is an FDA-cleared digital therapeutic program for Irritable Bowel Syndrome (IBS). This program provides a personalized and effective approach to managing IBS, offering real relief to patients.
Read full description
Mahanatx's business model revolves around working with expert clinicians, designers, and engineers to develop these digital programs. They are committed to demonstrating the effectiveness of their programs through rigorous clinical trials. This commitment to testing not only ensures the efficacy of their products but also aids in gaining regulatory clearance from bodies like the FDA.
The company serves a broad range of clients, primarily patients suffering from conditions like IBS. However, their programs are also beneficial to healthcare providers, as they can recommend or prescribe these digital therapeutics to their patients, strengthening the patient-provider relationship.
Mahanatx generates revenue through the sale of their digital therapeutic programs. As these programs are recommended or prescribed by healthcare providers, they have a steady stream of potential customers. Additionally, the company places a high emphasis on data security, ensuring that patient information is always protected.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 66.4/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Digital Therapeutics, Tech for Biotech and Pharma, Tech for Patients, Hard Tech
- Business model
- Manufacturing, SaaS
- Client focus
- b2b, b2c
Latest news
Press, funding announcements and product moves mentioning Mahana Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jan 2022 | $0 | — | Undisclosed | ↗ |
| SERIES BOther financing | Aug 2021 | $61M | $244M | Lux Capital · Main Street Advisors · KKCG · JAZZ Venture Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mahana Therapeutics is 1.6K monthly website visits, down 38.5% over the last three months. Mahana Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- JPJAZZ Venture Partners
Lux Capital
Series A4 investors entered at this stage
Outsized Ventures
Gurnet Point Capital- MAMain Street Advisors
KKCG
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mahana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mahana Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.